Advertisement
| data analysis in pharma industry: Multivariate Analysis in the Pharmaceutical Industry Ana Patricia Ferreira, Jose C. Menezes, Mike Tobyn, 2018-04-24 Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with perspectives on the applications of these methods that allow for testing, monitoring and controlling products and processes. The book seeks to put multivariate analysis into a pharmaceutical context for the benefit of pharmaceutical practitioners, potential practitioners, managers and regulators. Users will find a resources that addresses an unmet need on how pharmaceutical industry professionals can extract value from data that is routinely collected on products and processes, especially as these techniques become more widely used, and ultimately, expected by regulators. - Targets pharmaceutical industry practitioners and regulatory staff by addressing industry specific challenges - Includes case studies from different pharmaceutical companies and across product lifecycle of to introduce readers to the breadth of applications - Contains information on the current regulatory framework which will shape how multivariate analysis (MVA) is used in years to come |
| data analysis in pharma industry: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry Stephanie K. Ashenden, 2021-04-23 The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics. - Demonstrates how the prediction of toxic effects is performed, how to reduce costs in testing compounds, and its use in animal research - Written by the industrial teams who are conducting the work, showcasing how the technology has improved and where it should be further improved - Targets materials for a better understanding of techniques from different disciplines, thus creating a complete guide |
| data analysis in pharma industry: Applied Statistics in the Pharmaceutical Industry Steven P. Millard, Andreas Krause, 2013-11-09 Providing a general guide to statistical methods used in the pharmaceutical industry, and illustrating how to use S-PLUS to implement these methods, the book explains why S-PLUS is a useful software package and discusses the results and implications of each particular application. It is targeted at graduates in biostatistics, statisticians involved in the industry as research scientists, regulators, academics, and/or consultants who want to know more about how to use S-PLUS and learn about other sub-fields within the industry, as well as statisticians in other fields who want to know more about statistical applications in the pharmaceutical industry. |
| data analysis in pharma industry: Trends and Innovations in Information Systems and Technologies Álvaro Rocha, Hojjat Adeli, Luís Paulo Reis, Sandra Costanzo, Irena Orovic, Fernando Moreira, 2020-05-18 This book gathers selected papers presented at the 2020 World Conference on Information Systems and Technologies (WorldCIST’20), held in Budva, Montenegro, from April 7 to 10, 2020. WorldCIST provides a global forum for researchers and practitioners to present and discuss recent results and innovations, current trends, professional experiences with and challenges regarding various aspects of modern information systems and technologies. The main topics covered are A) Information and Knowledge Management; B) Organizational Models and Information Systems; C) Software and Systems Modeling; D) Software Systems, Architectures, Applications and Tools; E) Multimedia Systems and Applications; F) Computer Networks, Mobility and Pervasive Systems; G) Intelligent and Decision Support Systems; H) Big Data Analytics and Applications; I) Human–Computer Interaction; J) Ethics, Computers & Security; K) Health Informatics; L) Information Technologies in Education; M) Information Technologies in Radiocommunications; and N) Technologies for Biomedical Applications. |
| data analysis in pharma industry: Business Intelligence Demystified Anoop Kumar V K, 2021-09-25 Clear your doubts about Business Intelligence and start your new journey KEY FEATURES ● Includes successful methods and innovative ideas to achieve success with BI. ● Vendor-neutral, unbiased, and based on experience. ● Highlights practical challenges in BI journeys. ● Covers financial aspects along with technical aspects. ● Showcases multiple BI organization models and the structure of BI teams. DESCRIPTION The book demystifies misconceptions and misinformation about BI. It provides clarity to almost everything related to BI in a simplified and unbiased way. It covers topics right from the definition of BI, terms used in the BI definition, coinage of BI, details of the different main uses of BI, processes that support the main uses, side benefits, and the level of importance of BI, various types of BI based on various parameters, main phases in the BI journey and the challenges faced in each of the phases in the BI journey. It clarifies myths about self-service BI and real-time BI. The book covers the structure of a typical internal BI team, BI organizational models, and the main roles in BI. It also clarifies the doubts around roles in BI. It explores the different components that add to the cost of BI and explains how to calculate the total cost of the ownership of BI and ROI for BI. It covers several ideas, including unconventional ideas to achieve BI success and also learn about IBI. It explains the different types of BI architectures, commonly used technologies, tools, and concepts in BI and provides clarity about the boundary of BI w.r.t technologies, tools, and concepts. The book helps you lay a very strong foundation and provides the right perspective about BI. It enables you to start or restart your journey with BI. WHAT YOU WILL LEARN ● Builds a strong conceptual foundation in BI. ● Gives the right perspective and clarity on BI uses, challenges, and architectures. ● Enables you to make the right decisions on the BI structure, organization model, and budget. ● Explains which type of BI solution is required for your business. ● Applies successful BI ideas. WHO THIS BOOK IS FOR This book is a must-read for business managers, BI aspirants, CxOs, and all those who want to drive the business value with data-driven insights. TABLE OF CONTENTS 1. What is Business Intelligence? 2. Why do Businesses need BI? 3. Types of Business Intelligence 4. Challenges in Business Intelligence 5. Roles in Business Intelligence 6. Financials of Business Intelligence 7. Ideas for Success with BI 8. Introduction to IBI 9. BI Architectures 10. Demystify Tech, Tools, and Concepts in BI |
| data analysis in pharma industry: Secondary Analysis of Electronic Health Records MIT Critical Data, 2016-09-09 This book trains the next generation of scientists representing different disciplines to leverage the data generated during routine patient care. It formulates a more complete lexicon of evidence-based recommendations and support shared, ethical decision making by doctors with their patients. Diagnostic and therapeutic technologies continue to evolve rapidly, and both individual practitioners and clinical teams face increasingly complex ethical decisions. Unfortunately, the current state of medical knowledge does not provide the guidance to make the majority of clinical decisions on the basis of evidence. The present research infrastructure is inefficient and frequently produces unreliable results that cannot be replicated. Even randomized controlled trials (RCTs), the traditional gold standards of the research reliability hierarchy, are not without limitations. They can be costly, labor intensive, and slow, and can return results that are seldom generalizable to every patient population. Furthermore, many pertinent but unresolved clinical and medical systems issues do not seem to have attracted the interest of the research enterprise, which has come to focus instead on cellular and molecular investigations and single-agent (e.g., a drug or device) effects. For clinicians, the end result is a bit of a “data desert” when it comes to making decisions. The new research infrastructure proposed in this book will help the medical profession to make ethically sound and well informed decisions for their patients. |
| data analysis in pharma industry: Bad Pharma Ben Goldacre, 2014-04 Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc. |
| data analysis in pharma industry: Emergence of Pharmaceutical Industry Growth with Industrial IoT Approach Valentina Emilia Balas, Vijender Kumar Solanki, Raghvendra Kumar, 2019-09-24 Emergence of Pharmaceutical Industry Growth with Industrial IoT Approach uses an innovative approach to explore how the Internet of Things (IoT) and big data can improve approaches, create efficiencies and make discoveries. Rapid growth of the IoT has encouraged many companies in the manufacturing sector to make use of this technology to unlock its potential. Pharmaceutical manufacturing companies are no exception to this, as IoT has the potential to revolutionize aspects of the pharmaceutical manufacturing process, from drug discovery to manufacturing. Using clear, concise language and real world case studies, this book discusses systems level from both a human-factors point-of-view and the perspective of networking, databases, privacy and anti-spoofing. The wide variety of topics presented offers readers multiple perspectives on a how to integrate the Internet of Things into pharmaceutical manufacturing. - Covers efficiency improvements of pharmaceutical manufacturing through IoT/Big Data approaches - Explores cutting-edge technologies through sensor enabled environment in the pharmaceutical industry - Discusses the systems level from both a human-factors point-of-view and the perspective of networking, databases, privacy and anti-spoofing |
| data analysis in pharma industry: Sharing Clinical Trial Data Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data, 2015-04-20 Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients. |
| data analysis in pharma industry: Nonclinical Statistics for Pharmaceutical and Biotechnology Industries Lanju Zhang, 2016-01-13 This book serves as a reference text for regulatory, industry and academic statisticians and also a handy manual for entry level Statisticians. Additionally it aims to stimulate academic interest in the field of Nonclinical Statistics and promote this as an important discipline in its own right. This text brings together for the first time in a single volume a comprehensive survey of methods important to the nonclinical science areas within the pharmaceutical and biotechnology industries. Specifically the Discovery and Translational sciences, the Safety/Toxiology sciences, and the Chemistry, Manufacturing and Controls sciences. Drug discovery and development is a long and costly process. Most decisions in the drug development process are made with incomplete information. The data is rife with uncertainties and hence risky by nature. This is therefore the purview of Statistics. As such, this book aims to introduce readers to important statistical thinking and its application in these nonclinical areas. The chapters provide as appropriate, a scientific background to the topic, relevant regulatory guidance, current statistical practice, and further research directions. |
| data analysis in pharma industry: Statistical Applications for Chemistry, Manufacturing and Controls (CMC) in the Pharmaceutical Industry Richard K. Burdick, David J. LeBlond, Lori B. Pfahler, Jorge Quiroz, Leslie Sidor, Kimberly Vukovinsky, Lanju Zhang, 2017-02-14 This book examines statistical techniques that are critically important to Chemistry, Manufacturing, and Control (CMC) activities. Statistical methods are presented with a focus on applications unique to the CMC in the pharmaceutical industry. The target audience consists of statisticians and other scientists who are responsible for performing statistical analyses within a CMC environment. Basic statistical concepts are addressed in Chapter 2 followed by applications to specific topics related to development and manufacturing. The mathematical level assumes an elementary understanding of statistical methods. The ability to use Excel or statistical packages such as Minitab, JMP, SAS, or R will provide more value to the reader. The motivation for this book came from an American Association of Pharmaceutical Scientists (AAPS) short course on statistical methods applied to CMC applications presented by four of the authors. One of the course participants asked us for a good reference book, and the only book recommended was written over 20 years ago by Chow and Liu (1995). We agreed that a more recent book would serve a need in our industry. Since we began this project, an edited book has been published on the same topic by Zhang (2016). The chapters in Zhang discuss statistical methods for CMC as well as drug discovery and nonclinical development. We believe our book complements Zhang by providing more detailed statistical analyses and examples. |
| data analysis in pharma industry: Lattice Deepayan Sarkar, 2008-02-15 Written by the author of the lattice system, this book describes lattice in considerable depth, beginning with the essentials and systematically delving into specific low levels details as necessary. No prior experience with lattice is required to read the book, although basic familiarity with R is assumed. The book contains close to 150 figures produced with lattice. Many of the examples emphasize principles of good graphical design; almost all use real data sets that are publicly available in various R packages. All code and figures in the book are also available online, along with supplementary material covering more advanced topics. |
| data analysis in pharma industry: Statistics In the Pharmaceutical Industry C. Ralph Buncher, Jia-Yeong Tsay, 2019-03-07 The growth of the pharmaceutical industry over the past decade is astounding, but the impact of this growth on statistics is somewhat confusing. While software has made analysis easier and more efficient, regulatory bodies now demand deeper and more complex analyses, and pharmacogenetic/genomic studies serve up an entirely new set of challenges. For more than two decades, Statistics in the Pharmaceutical Industry has been the definitive guide to sorting through the challenges in the industry, and this Third Edition continues that tradition. Updated and expanded to reflect the most recent trends and developments in the field, Statistics in the Pharmaceutical Industry, Third Edition presents chapters written by experts from both regulatory agencies and pharmaceutical companies who discuss everything from experimental design to post-marketing studies. This approach sheds light on what regulators consider acceptable methodologies and what methods have proven successful for industrial statisticians. Both new and revised chapters reflect the increasingly global nature of the industry as represented by authors from Japan and Europe, the increasing trend toward non-inferiority/equivalence testing, adaptive design in clinical trials, global harmonization of regulatory standards, and multiple comparison studies. The book also examines the latest considerations in anti-cancer studies. Statistics in the Pharmaceutical Industry, Third Edition demystifies the approval process by combining regulatory and industrial points of view, making it a must-read for anyone performing statistical analysis at any point in the drug approval process. |
| data analysis in pharma industry: Global Business Leadership Development for the Fourth Industrial Revolution Smith, Peter, Cockburn, Tom, 2020-09-25 As the world has adapted to the age of digital technology, present day business leaders are required to change with the times as well. Addressing and formatting their business practices to not only encompass digital technologies, but expand their capabilities, the leaders of today must be flexible and willing to familiarize themselves with all types of global business practices. Global Business Leadership Development for the Fourth Industrial Revolution is a collection of advanced research on the methods and tactics utilized to succeed as a leader in the digital age. While highlighting topics including data privacy, corporate governance, and risk management, this book is ideally designed for business professionals, administrators, managers, executives, researchers, academicians, and business students who want to improve their understanding of the strategic role of digital technologies in the global economy, in networks and organizations, in teams and work groups, in information systems, and at the level of individuals as actors in digitally networked environments |
| data analysis in pharma industry: Data Integrity and Data Governance R. D. McDowall, 2018-11-09 This book provides practical and detailed advice on how to implement data governance and data integrity for regulated analytical laboratories working in the pharmaceutical and allied industries. |
| data analysis in pharma industry: Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making Institute of Medicine, Roundtable on Research and Development of Drugs, Biologics, and Medical Devices, 1999-07-27 In an effort to increase knowledge and understanding of the process of assuring data quality and validity in clinical trials, the IOM hosted a workshop to open a dialogue on the process to identify and discuss issues of mutual concern among industry, regulators, payers, and consumers. The presenters and panelists together developed strategies that could be used to address the issues that were identified. This IOM report of the workshop summarizes the present status and highlights possible strategies for making improvements to the education of interested and affected parties as well as facilitating future planning. |
| data analysis in pharma industry: Research and Development in the Pharmaceutical Industry (A CBO Study) Congressional Budget Office, 2013-06-09 Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation... |
| data analysis in pharma industry: The Prevention and Treatment of Missing Data in Clinical Trials National Research Council, Division of Behavioral and Social Sciences and Education, Committee on National Statistics, Panel on Handling Missing Data in Clinical Trials, 2010-12-21 Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data. |
| data analysis in pharma industry: Forecasting for the Pharmaceutical Industry Arthur G. Cook, 2006 The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. |
| data analysis in pharma industry: Statistics In the Pharmaceutical Industry, 3rd Edition C. Ralph Buncher, Jia-Yeong Tsay, 2005-09-28 The growth of the pharmaceutical industry over the past decade is astounding, but the impact of this growth on statistics is somewhat confusing. While software has made analysis easier and more efficient, regulatory bodies now demand deeper and more complex analyses, and pharmacogenetic/genomic studies serve up an entirely new set of challenges. For more than two decades, Statistics in the Pharmaceutical Industry has been the definitive guide to sorting through the challenges in the industry, and this Third Edition continues that tradition. Updated and expanded to reflect the most recent trends and developments in the field, Statistics in the Pharmaceutical Industry, Third Edition presents chapters written by experts from both regulatory agencies and pharmaceutical companies who discuss everything from experimental design to post-marketing studies. This approach sheds light on what regulators consider acceptable methodologies and what methods have proven successful for industrial statisticians. Both new and revised chapters reflect the increasingly global nature of the industry as represented by authors from Japan and Europe, the increasing trend toward non-inferiority/equivalence testing, adaptive design in clinical trials, global harmonization of regulatory standards, and multiple comparison studies. The book also examines the latest considerations in anti-cancer studies. Statistics in the Pharmaceutical Industry, Third Edition demystifies the approval process by combining regulatory and industrial points of view, making it a must-read for anyone performing statistical analysis at any point in the drug approval process. |
| data analysis in pharma industry: Statistical Methodology in the Pharmaceutical Sciences D. A. Berry, 2019-10-07 A state-of-the-art handbook of statistical analysis for use in the pharmaceutical industry. Areas covered in this reference/text include: bioavailability, repeated-measures designs, dose-response, population models, multicenter trials, handling dropouts, survival analysis, robust data analysis, cate |
| data analysis in pharma industry: Bayesian Analysis with R for Drug Development Harry Yang, Steven Novick, 2019-06-26 Drug development is an iterative process. The recent publications of regulatory guidelines further entail a lifecycle approach. Blending data from disparate sources, the Bayesian approach provides a flexible framework for drug development. Despite its advantages, the uptake of Bayesian methodologies is lagging behind in the field of pharmaceutical development. Written specifically for pharmaceutical practitioners, Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies, describes a wide range of Bayesian applications to problems throughout pre-clinical, clinical, and Chemistry, Manufacturing, and Control (CMC) development. Authored by two seasoned statisticians in the pharmaceutical industry, the book provides detailed Bayesian solutions to a broad array of pharmaceutical problems. Features Provides a single source of information on Bayesian statistics for drug development Covers a wide spectrum of pre-clinical, clinical, and CMC topics Demonstrates proper Bayesian applications using real-life examples Includes easy-to-follow R code with Bayesian Markov Chain Monte Carlo performed in both JAGS and Stan Bayesian software platforms Offers sufficient background for each problem and detailed description of solutions suitable for practitioners with limited Bayesian knowledge Harry Yang, Ph.D., is Senior Director and Head of Statistical Sciences at AstraZeneca. He has 24 years of experience across all aspects of drug research and development and extensive global regulatory experiences. He has published 6 statistical books, 15 book chapters, and over 90 peer-reviewed papers on diverse scientific and statistical subjects, including 15 joint statistical works with Dr. Novick. He is a frequent invited speaker at national and international conferences. He also developed statistical courses and conducted training at the FDA and USP as well as Peking University. Steven Novick, Ph.D., is Director of Statistical Sciences at AstraZeneca. He has extensively contributed statistical methods to the biopharmaceutical literature. Novick is a skilled Bayesian computer programmer and is frequently invited to speak at conferences, having developed and taught courses in several areas, including drug-combination analysis and Bayesian methods in clinical areas. Novick served on IPAC-RS and has chaired several national statistical conferences. |
| data analysis in pharma industry: Innovation and Marketing in the Pharmaceutical Industry Min Ding, Jehoshua Eliashberg, Stefan Stremersch, 2013-10-31 The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike. |
| data analysis in pharma industry: Statistics In the Pharmaceutical Industry, 3rd Edition Charles Ralph Buncher, Jia-Yeong Tsay, 1993-11-17 This rewritten and updated second edition provides comprehensive information on the wide-ranging applications of statistics in the pharmacological field. Focusing on practical aspects, it sets out to bridge the gap between industry and academia.;Reflecting the changes that have taken place since publication of the first edition, this volume covers new topics such as: cancer clinical trials, clinical trials of AIDS patients and animal tumorigenicity studies; the development of antiepileptic drugs; the role of epidemiology in postmarketing trials and adverse drug experience; computer-assisted new drug application (CANDA) submissions; contract research organizations; interim analysis in clinical trials; and room-temperature tests for the stability of drugs.;This work is intended as: a reference for statisticians, biostatisticians, pharmacologists, administrators, managers, and scientists in the pharmaceutical industry; and a text for graduate students taking courses in applied statistics or pharmaceutical statistics. |
| data analysis in pharma industry: Improving and Accelerating Therapeutic Development for Nervous System Disorders Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2014-02-06 Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials. |
| data analysis in pharma industry: Quantitative Methods in Pharmaceutical Research and Development Olga V. Marchenko, Natallia V. Katenka, 2020-09-24 This contributed volume presents an overview of concepts, methods, and applications used in several quantitative areas of drug research, development, and marketing. Chapters bring together the theories and applications of various disciplines, allowing readers to learn more about quantitative fields, and to better recognize the differences between them. Because it provides a thorough overview, this will serve as a self-contained resource for readers interested in the pharmaceutical industry, and the quantitative methods that serve as its foundation. Specific disciplines covered include: Biostatistics Pharmacometrics Genomics Bioinformatics Pharmacoepidemiology Commercial analytics Operational analytics Quantitative Methods in Pharmaceutical Research and Development is ideal for undergraduate students interested in learning about real-world applications of quantitative methods, and the potential career options open to them. It will also be of interest to experts working in these areas. |
| data analysis in pharma industry: GAMP 5 Sion Wyn, 2008 GAMP 5 provides pragmatic and practical industry guidance to achieve compliant computerized systems fit for intended use in an efficient and effective manner. This technical document describes a flexible risk-based approach to compliant GxP regulated computerized systems, based on scalable specification and verification. It points to the future of computer systems compliance by centering on principles behind major industry developments such as PQLI; ICH Q8, Q9, Q10; and ASTM E2500. This revolutionary Guide addresses the entire lifecycle of an automated system and its applicability to a wide range of information systems, lab equipment, integrated manufacturing systems, and IT infrastructures. It contains new information on outsourcing, electronic batch recording, end user applications (such as spreadsheets and small database applications), and patch management. |
| data analysis in pharma industry: Chemical Engineering in the Pharmaceutical Industry David J. am Ende, 2011-03-10 This book deals with various unique elements in the drug development process within chemical engineering science and pharmaceutical R&D. The book is intended to be used as a professional reference and potentially as a text book reference in pharmaceutical engineering and pharmaceutical sciences. Many of the experimental methods related to pharmaceutical process development are learned on the job. This book is intended to provide many of those important concepts that R&D Engineers and manufacturing Engineers should know and be familiar if they are going to be successful in the Pharmaceutical Industry. These include basic analytics for quantitation of reaction components– often skipped in ChE Reaction Engineering and kinetics books. In addition Chemical Engineering in the Pharmaceutical Industry introduces contemporary methods of data analysis for kinetic modeling and extends these concepts into Quality by Design strategies for regulatory filings. For the current professionals, in-silico process modeling tools that streamline experimental screening approaches is also new and presented here. Continuous flow processing, although mainstream for ChE, is unique in this context given the range of scales and the complex economics associated with transforming existing batch-plant capacity. The book will be split into four distinct yet related parts. These parts will address the fundamentals of analytical techniques for engineers, thermodynamic modeling, and finally provides an appendix with common engineering tools and examples of their applications. |
| data analysis in pharma industry: Statistical Procedures for the Medical Device Industry Wayne A. Taylor, 2017 |
| data analysis in pharma industry: Solid State Development and Processing of Pharmaceutical Molecules Michael Gruss, 2021-11-15 Solid State Development and Processing of Pharmaceutical Molecules A guide to the lastest industry principles for optimizing the production of solid state active pharmaceutical ingredients Solid State Development and Processing of Pharmaceutical Molecules is an authoritative guide that covers the entire pharmaceutical value chain. The authors—noted experts on the topic—examine the importance of the solid state form of chemical and biological drugs and review the development, production, quality control, formulation, and stability of medicines. The book explores the most recent trends in the digitization and automation of the pharmaceutical production processes that reflect the need for consistent high quality. It also includes information on relevant regulatory and intellectual property considerations. This resource is aimed at professionals in the pharmaceutical industry and offers an in-depth examination of the commercially relevant issues facing developers, producers and distributors of drug substances. This important book: Provides a guide for the effective development of solid drug forms Compares different characterization methods for solid state APIs Offers a resource for understanding efficient production methods for solid state forms of chemical and biological drugs Includes information on automation, process control, and machine learning as an integral part of the development and production workflows Covers in detail the regulatory and quality control aspects of drug development Written for medicinal chemists, pharmaceutical industry professionals, pharma engineers, solid state chemists, chemical engineers, Solid State Development and Processing of Pharmaceutical Molecules reviews information on the solid state of active pharmaceutical ingredients for their efficient development and production. |
| data analysis in pharma industry: Artificial Intelligence in Drug Discovery Nathan Brown, 2020-11-04 Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. |
| data analysis in pharma industry: Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry Mithun Nandy, 2021-12-03 The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach. |
| data analysis in pharma industry: Practical Statistics for Pharmaceutical Analysis James E. De Muth, 2019-12-10 This is an introductory statistics book designed to provide scientists with practical information needed to apply the most common statistical tests to laboratory research data. The book is designed to be practical and applicable, so only minimal information is devoted to theory or equations. Emphasis is placed on the underlying principles for effective data analysis and survey the statistical tests. It is of special value for scientists who have access to Minitab software. Examples are provides for all the statistical tests and explanation of the interpretation of these results presented with Minitab (similar to results for any common software package). The book is specifically designed to contribute to the AAPS series on advances in the pharmaceutical sciences. It benefits professional scientists or graduate students who have not had a formal statistics class, who had bad experiences in such classes, or who just fear/don’t understand statistics. Chapter 1 focuses on terminology and essential elements of statistical testing. Statistics is often complicated by synonyms and this chapter established the terms used in the book and how rudiments interact to create statistical tests. Chapter 2 discussed descriptive statistics that are used to organize and summarize sample results. Chapter 3 discussed basic assumptions of probability, characteristics of a normal distribution, alternative approaches for non-normal distributions and introduces the topic of making inferences about a larger population based on a small sample from that population. Chapter 4 discussed hypothesis testing where computer output is interpreted and decisions are made regarding statistical significance. This chapter also deasl with the determination of appropriate sample sizes. The next three chapters focus on tests that make decisions about a population base on a small subset of information. Chapter 5 looks at statistical tests that evaluate where a significant difference exists. In Chapter 6 the tests try to determine the extent and importance of relationships. In contrast to fifth chapter, Chapter 7 presents tests that evaluate the equivalence, not the difference between levels being tested. The last chapter deals with potential outlier or aberrant values and how to statistically determine if they should be removed from the sample data. Each statistical test presented includes an example problem with the resultant software output and how to interpret the results. Minimal time is spent on the mathematical calculations or theory. For those interested in the associated equations, supplemental figures are presented for each test with respective formulas. In addition, Appendix D presents the equations and proof for every output result for the various examples. Examples and results from the appropriate statistical results are displayed using Minitab 18Ò. In addition to the results, the required steps to analyze data using Minitab are presented with the examples for those having access to this software. Numerous other software packages are available, including based data analysis with Excel. |
| data analysis in pharma industry: Applying Predictive Analytics Within the Service Sector Sahu, Rajendra, Dash, Manoj, Kumar, Anil, 2017-02-07 Value creation is a prime concern for any contemporary business. This can be accomplished through the incorporation of various techniques and processes, such as the integration of analytics to improve business functions. Applying Predictive Analytics Within the Service Sector is a pivotal reference source for the latest innovative perspectives on the incorporation of analysis techniques to enhance business performance. Examining a wide range of relevant topics, such as alternative clustering, recommender systems, and social media tools, this book is ideally designed for researchers, academics, students, professionals, and practitioners seeking scholarly material on business improvement in the service industry. |
| data analysis in pharma industry: Chemical Engineering in the Pharmaceutical Industry Mary T. am Ende, David J. am Ende, 2019-04-01 A guide to the important chemical engineering concepts for the development of new drugs, revised second edition The revised and updated second edition of Chemical Engineering in the Pharmaceutical Industry offers a guide to the experimental and computational methods related to drug product design and development. The second edition has been greatly expanded and covers a range of topics related to formulation design and process development of drug products. The authors review basic analytics for quantitation of drug product quality attributes, such as potency, purity, content uniformity, and dissolution, that are addressed with consideration of the applied statistics, process analytical technology, and process control. The 2nd Edition is divided into two separate books: 1) Active Pharmaceutical Ingredients (API’s) and 2) Drug Product Design, Development and Modeling. The contributors explore technology transfer and scale-up of batch processes that are exemplified experimentally and computationally. Written for engineers working in the field, the book examines in-silico process modeling tools that streamline experimental screening approaches. In addition, the authors discuss the emerging field of continuous drug product manufacturing. This revised second edition: Contains 21 new or revised chapters, including chapters on quality by design, computational approaches for drug product modeling, process design with PAT and process control, engineering challenges and solutions Covers chemistry and engineering activities related to dosage form design, and process development, and scale-up Offers analytical methods and applied statistics that highlight drug product quality attributes as design features Presents updated and new example calculations and associated solutions Includes contributions from leading experts in the field Written for pharmaceutical engineers, chemical engineers, undergraduate and graduation students, and professionals in the field of pharmaceutical sciences and manufacturing, Chemical Engineering in the Pharmaceutical Industry, Second Edition contains information designed to be of use from the engineer's perspective and spans information from solid to semi-solid to lyophilized drug products. |
| data analysis in pharma industry: Small Clinical Trials Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Small-Number-Participant Clinical Research Trials, 2001-01-01 Clinical trials are used to elucidate the most appropriate preventive, diagnostic, or treatment options for individuals with a given medical condition. Perhaps the most essential feature of a clinical trial is that it aims to use results based on a limited sample of research participants to see if the intervention is safe and effective or if it is comparable to a comparison treatment. Sample size is a crucial component of any clinical trial. A trial with a small number of research participants is more prone to variability and carries a considerable risk of failing to demonstrate the effectiveness of a given intervention when one really is present. This may occur in phase I (safety and pharmacologic profiles), II (pilot efficacy evaluation), and III (extensive assessment of safety and efficacy) trials. Although phase I and II studies may have smaller sample sizes, they usually have adequate statistical power, which is the committee's definition of a large trial. Sometimes a trial with eight participants may have adequate statistical power, statistical power being the probability of rejecting the null hypothesis when the hypothesis is false. Small Clinical Trials assesses the current methodologies and the appropriate situations for the conduct of clinical trials with small sample sizes. This report assesses the published literature on various strategies such as (1) meta-analysis to combine disparate information from several studies including Bayesian techniques as in the confidence profile method and (2) other alternatives such as assessing therapeutic results in a single treated population (e.g., astronauts) by sequentially measuring whether the intervention is falling above or below a preestablished probability outcome range and meeting predesigned specifications as opposed to incremental improvement. |
| data analysis in pharma industry: Pharmaceutical Data Mining Konstantin V. Balakin, 2009-11-19 Leading experts illustrate how sophisticated computational data mining techniques can impact contemporary drug discovery and development In the era of post-genomic drug development, extracting and applying knowledge from chemical, biological, and clinical data is one of the greatest challenges facing the pharmaceutical industry. Pharmaceutical Data Mining brings together contributions from leading academic and industrial scientists, who address both the implementation of new data mining technologies and application issues in the industry. This accessible, comprehensive collection discusses important theoretical and practical aspects of pharmaceutical data mining, focusing on diverse approaches for drug discovery—including chemogenomics, toxicogenomics, and individual drug response prediction. The five main sections of this volume cover: A general overview of the discipline, from its foundations to contemporary industrial applications Chemoinformatics-based applications Bioinformatics-based applications Data mining methods in clinical development Data mining algorithms, technologies, and software tools, with emphasis on advanced algorithms and software that are currently used in the industry or represent promising approaches In one concentrated reference, Pharmaceutical Data Mining reveals the role and possibilities of these sophisticated techniques in contemporary drug discovery and development. It is ideal for graduate-level courses covering pharmaceutical science, computational chemistry, and bioinformatics. In addition, it provides insight to pharmaceutical scientists, principal investigators, principal scientists, research directors, and all scientists working in the field of drug discovery and development and associated industries. |
| data analysis in pharma industry: Global Supply Chains in the Pharmaceutical Industry Nozari, Hamed, Szmelter, Agnieszka, 2018-11-09 In a rapidly growing global economy, where there is a constant emergence of new business models and dynamic changes to the business ecosystem, there is a need for the integration of traditional, new, and hybrid concepts in the complex structure of supply chain management. Within the fast-paced pharmaceutical industry, product strategy, life cycles, and distribution must maintain the highest level of agility. Therefore, organizations need strong supply chain capabilities to profitably compete in the marketplace. Global Supply Chains in the Pharmaceutical Industry provides innovative insights into the efforts needed to build and maintain a strong supply chain network in order to achieve efficient fulfillment of demand, drive outstanding customer value, enhance organizational responsiveness, and build network resiliency. This publication is designed for supply chain managers, policymakers, researchers, academicians, and students, and covers topics centered on economic cycles, sustainable development, and new forces in the global economy. |
| data analysis in pharma industry: SAS Programming in the Pharmaceutical Industry Jack Shostak, SAS Institute, 2005 This real-world reference for clinical trial SAS programming is packed with solutions that can be applied day-to-day problems. Organized to reflect the statistical programmers workflow, this user-friendly text begins with an introduction to the working environment, then presents chapters on importing and massaging data into analysis data sets, producing clinical trial output, and exporting data. |
| data analysis in pharma industry: Statistical Methodology in the Pharmaceutical Sciences D. A. Berry, 1989-09-28 A state-of-the-art handbook of statistical analysis for use in the pharmaceutical industry. Areas covered in this reference/text include: bioavailability, repeated-measures designs, dose-response, population models, multicenter trials, handling dropouts, survival analysis, robust data analysis, cate |
Unlocking the full potential of data and analytics in pharma
Companies will need to collect, store and process data, and use analytical solutions to derive insights for efficient business decision-making. The data they collect will power a wide range of …
6 Ways Pharmaceutical Companies are Using Data Analytics …
Here are 6 ways that pharmaceutical companies can use Data Analytics to generate business value and drive innovation.
Data Integrity and Compliance With CGMP Guidance for …
How does FDA recommend data integrity problems identified during inspections, in warning letters, or in other regulatory actions be addressed?...
Information Management: The Key to Commercial Success in …
If pharma companies want to take data warehousing one step further and get fast, effective analytics, they should also consider an analytic data mart. An analytic data mart allows …
Breaking Down Silos: Empowering Pharma Commercial Teams …
AI-driven analytics and integrated visualization transform large datasets into actionable insights, enhancing decision-making across commercial, customer engagement, and market access …
Big Pharma; Big Data - Big Deal? Yes; Really! - Infosys
industry currently -- declining R&D productivity, globalization of the supply chain, country-specific regulatory compliance requirements, rising commercial demands -- can be addressed very …
How pharma can accelerate business impact from advanced …
pharma company has systematically cracked the code. However, there are exciting examples of impact across the industry (and in other industries) that offer lessons for how pharma can …
DATA ANALYTICS AND REPORTING IN PHARMA - StatSoft
In a highly regulated industry like pharmaceuticals, companies have to document and man- age their production processes and according data continuously, as well as put them to use in …
Cliniminds, Think-I & Team of Business Analytics and Consulting
Big Data and Data Science: This would provide knowledge regarding role of big data analytics in pharmaceutical industry. Focus of this course would be to make graduates aware of …
Big Data in Pharma World: What & How!! We Want?
There are five ways that Big Data is making major changes to the industry. The opportunities for pharmaceutical companies to make use of analytics are manifold – from analyzing patient …
Big data collection in pharmaceutical manufacturing and its …
The primary data sources are laboratory analysis results of incoming raw materials (excipients and API), of the intermediate product (tablet cores), and of the final product.
Pharmaceutical analysis techniques - thepharmajournal.com
From classical methods such as titration and gravimetric analysis to modern instrumental techniques like chromatography, spectroscopy, and mass spectrometry, each method offers …
Pharma Data Analytics (Pharma Intelligence): Opportunities …
In this context, data analytics offers a set of appropriate statistical techniques that, combined with Artificial Intelligence (AI) have allowed overcoming the challenges imposed by the …
Statistical Programming in the Pharmaceutical Industry: …
In pharmaceutical product development, statistical programming and the analysis of clinical trial data has always played a key role in helping to deliver medicines to patients. Over the last …
Pharma Analytics A Dynamic Approach to Segmentation
The pharma industry stands at a pivotal juncture, contemplating how to approach targeting and segmentation, given the vast volume and velocity of data available today compared to a …
BIG DATA Pharmaceutical Industry - ddismart.com
Big Data analytics – which includes data integration, data mining, and analytics etc. – will help pharmaceutical industry make smarter decisions. With varied data sources being added …
How Automation, AI, and Data Integration are Transforming …
Data must be readily available and digestible for signal detection and for monitoring risks and benefits in real-time, especially for small to mid-sized pharma businesses. User-friendly data …
Data analytics in pharmaceutical supply chains: state of the art,
data analytics in PSCs (DA-PSC), which is expected to expand greatly in upcoming years. This article reviews existing literature in the domain to analyse its current state
Emerging Challenges for Data Integrity in the Pharmaceutical …
ng over the last 20 years, especially in pharmaceutical production. Businesses can now monitor, analyse and model far more data than ever before, whic. has led to significant advances in …
Data Integrity – Focus on Quality Culture
Data Integrity = a complete, consistent, and accurate data to assure patient safety and product quality. Take action– take all the input and create a comprehensive plan.
African Pharmaceutical Sector Landscape Analysis
available data, of potential opportunities and challenges in further pharmaceutical sector development to achieve the objectives of trade and public health. Policy recommendations …
Pharmaceutical quality control and assurance
pharmaceutical industry, including manufacturers, regulators, quality assurance professionals, and technology experts. Collect secondary data from reputable sources such as government …
CRO Industry Report - PPD, Inc.
pharma and biopharma companies to opt for outsourcing. The CRO services market was estimated to be worth $76.6 billion in 2023 and is projected to reach $127.3 billion by 2028, …
James E. De Muth Practical Statistics for Pharmaceutical …
tical analysis. Some questions and decisions are clearly in the analytical domain and need to be addressed by the scientist designing the study and collecting the data. Other questions and …
Competitor Analysis in Pharma Companies and their …
Collect and analyze data on competitors: The third step is to collect and analyze relevant data on each competitor. This can include quantitative data (such as sales, revenue, market share, …
Data analytics in pharmaceutical supply chains: state of the art,
Data analytics (DA) or big data analytics, is defined as the field of study that focuses on deriving knowledge and gaining insights from data (Tiwari, Wee, and Daryanto 2018; Schuh et al. 2019).
Analyzing the state of Data Integrity Compliance in the Indian ...
pharmaceutical industry in India and has forced companies to rethink their methods of ensuring quality and compliance, and sustaining business. In line with this, EY Fraud Investigation & …
MALAYSIA’S PHARMACEUTICAL INDUSTRY: A FAST …
MALAYSIA’S PHARMACEUTICAL INDUSTRY: 05 A FAST-GROWING FORCE RISING DEMAND FOR PHARMACEUTICALS The pharmaceutical industry in Malaysia has seen …
'Packages' in R for Clinical Data Analysis, Let's Demystify
The Pharmaceutical Industry is seeking better alternative technologies and tools which are sustainable and can provide optimal solutions to address Industry challenges effectively. Are …
RISK ASSESSMENT APPROACH AND ITS APPLICATION IN …
methods widely used in the industry for risk management. understanding. It methodically breaks down Basic risk management facilitation methods (flowcharts, check sheets, Cause & Effect …
Demand Forecasting Analysis for Pharma Retail
Data analysis is needed for trends, seasonality, stockouts, and demand stability. Followed by the application of various ... of forecasting in the retail pharma industry followed by a segment …
TREND AND OUT-OF-TREND ANALYSIS FOR …
the industry that lends itself to consistent interpretation and uniformapplication. ... Let’s now define an established expected pattern of data or events as the trend. Then my neighbor’s …
Documentation and Data Integrity in Pharmaceutical Industry
To guarantee that data are accessible for statistical analysis, evaluation, and validation. Thus, it is understood that documentation is a crucial requirement of the phar- ... 11.1.2 Data Integrity in …
Indian Pharmaceutical Industry - ICRA
Jun 28, 2024 · 4 Analytical Contact Details Name Designation Email Contact Number Shamsher Dewan Group Head shamsherd@icraindia.com 0124 – 4545 328 Kinjal Shah Co-Group Head …
Digitalization of the Value Chain - smart-pharma.com
Pharma companies are directly concerned by the growing importance of digitalization of their business model and the arrival of new entrants likely to be competitors and/or partners …
THE ECONOMIC IMPACT OF THE GLOBAL PHARMACEUTICAL …
based on inter-industry and inter-country linkages. chemical industry is the top supplier and human health services industry is the top buyer of the pharmaceutical industry the chemical …
HOW TO MAKE PHARMA MANUFACTURING MORE ENERGY …
3 4 Plan de sobriété énergétique, 6.10.2022 5 Le Monde, 19.9.2022 6 L’Usine Nouvelle, 26.8.2022 7 LEEM, 7.11.2022 8 ANSM, 26.10.2022 9 PV-magazine, 20.5.2021 10 …
Indian Pharmaceutical Market Quarterly Insights Q1 2021(Jan …
• Relative performance: 9% (Indian Pharma Cos); 7% (MNC Pharma Cos) for Q1 2021 • Intas, Torrent, Aristo and Glenmark led growth among Top 15 Indian Pharma Co’s while Mylan and …
Leading a Digital Transformation in the Pharmaceutical …
The pharmaceutical industry is fundamentally a data-driven business. 6 All along the value chain from research to market, we wrap our molecules around with data: to prove their mode of ac- …
Pharma outlook 2030: From evolution to revolution - KPMG
Pharma 2030 outlook Many of the developments in the pharmaceutical industry mirror those in the automotive sector. Like pharmaceuticals, the industry is relatively mature and made up of a …
Strategic Cost Management in Indian Pharmaceutical …
Data has collected from annual reports of the respective Pharmaceuticals companies, Publications of the companies, magazines, journals, online database. The period of the study …
Pharmaceutical industry profile - Economist Impact
Artificial intelligence in drug discovery market size, share & trends analysis report by application (drug optimization & repurposing, preclinical testing), by therapeutic area, by region, and …
A Comparative study of Financial Analysis of Pharmaceutical …
This research aims to assess the financial performance of the pharmaceutical industry by looking at the top ten companies, including Cipla, Dr. Reddy's Laboratories, Sun Pharma, Lupin Ltd., …
Data Warehousing in Pharmaceuticals and Healthcare: An …
analysis, data mining, trend identification, and respond to these trends in a beneficial way. Thus, it allows enterprises to cope with the well-known phenomenon of information overload. To be …
Cybersecurity in the Pharmaceutical Industry - Fortinet
As the pharmaceutical industry grows, the danger of cyber attacks increases, putting sensitive operational technology and patient data at risk. But while hackers are better equipped and …
Pharmaceutical Industry - PACRA
• The Global pharmaceutical industry is estimated to have grown to USD~1,250bln in CY21 (CY20: USD~1,228bln), posting a growth of ~1.8% YoY; the overall industry size is expected …
Annex 1 WHO good practices for pharmaceutical quality …
5. Data-processing equipment 6. Personnel 7. Premises 8. Equipment, instruments and other devices 9. Contracts Part two. Materials, equipment, instruments and other devices 10. …
TURKISH PHARMACEUTICAL INDUSTRY - İEİS
In this context, we consider compiling market and macroeconomic data and converting them into comprehensive analyses for the pharmaceutical industry as one of our priority areas of activity, …
CRO Industry Report - PPD, Inc.
dress data analysis and create efficiencies, development needs around emerging biopharma therapeutic candidates, as well as efforts to bring new therapeutics to market faster in the face …
Generative AI for Pharma Companies - Smart Pharma
Huma.AI launches industry’s first generative AI platform for life sciences –Smart Pharma Consulting Medical affairs can leverage generative AI to enhance medical data research and …
ANONYMOUS PATIENT LEVEL DATA PORTAL (APLD) - ITS …
biotech industry for with a significant focus on compliance and strategic “read the business” tools such as scorecards, technology portals and custom analytics Services o Products and Tools o …
Pharma Software - A Complete Overview - IJSHR
software in the pharma industry is clear, as it is essential to support the complex and highly regulated nature of drug development and commercialization. Each type of ... the collection, …
Gas Chromatography and its Applications in Pharmaceutical …
in the separation and analysis of compounds. Its versatility and precision have made it indispensable in research, industry and regulatory applications. Advances in column …
SI12_PharmaSUG2018_R for Clinical trials
SAS is leader for data analysis in health care industry being accepted by regulatory bodies worldwide. R is one of the open source software used in academic and other research firms. …
pharmacovigilance Using technology and analytics to enable …
Focus on risk/benefit analysis and signal management; need for advanced safety data analytics tools Consumerism is demanding increased focus on patient centricity Patient focused …
Approaches to Pharmaceutical Demand Forecasting - Mirador …
use as a basis for your forecast. Have you purchased secondary prescription or claims data, syndicated analysis, or conducted primary research? While these sources require additional …
Traceability: Not just about Data - PharmaSUG
In the clinical trial process, forward traceability is the ability to produce analysis result from raw data to study submission. The ability to trace processed data back to its source and the logic …
Culture of Quality: Data Integrity and CGMP Compliance
Apr 26, 2022 · Industry: Responsibility to ensure the safety, ... existing data . as new data Lack of RC analysis, inadequate . OOS investigations, inadequate CAPAs Lack of . controlled . access to
Revolutionizing Pharma: Unveiling the AI and LLM Trends in …
Jan 22, 2024 · meticulously tailored to address specific aspects of each industry segment. For example, to probe into the utilization of AI in data analysis within the phar-maceutical domain, …
Valuation Analysis of Indian Ph i l SPharmaceutical Sector
The Indian biotech industry has registered 18.5 percent growth in FY12. • Bio Pharma and the healthcare sector are the largest 11 6 14 Indian Biotech Industry (USDBn) component of the …
Data Integrity in the Pharmaceutical Industry - GMP-Verlag …
Data Integrity in the Pharmaceutical Industry . by Gary Bird . Data integrity has become the most recent inspectional “buzz word” in the pharmaceutical industry. Over the last 6 to 8 years, the …
The Implementation of Scrum in Pharmaceutical Data …
The Implementation of Scrum in Pharmaceutical Data Analytics and Statistical Programming Jagan Mohan Achi, Jazz Pharmaceuticals; Eliana D’Angelo, Scimitar, Inc. ABSTRACT Scrum …
Cliniminds, Think-I & Team of Business Analytics and Consulting
• Presecptions Data: Prescription data by products/ company/ Indications • Promotional Data: Pharma companies investment data by channels, which helps in calculating Share of Details …
SAUDI ARABIA PHARMA MARKET & REGULATORY REPORT
(Set up by Ministry of Commerce & Industry, Government of India) SAUDI ARABIA PHARMA MARKET & REGULATORY REPORT. Pharmexcil May 2020 ... Jamjoom Pharma and Saudi …
ANALYTICS KNOWLEDGE PHARMA DIVISION DEEP
Comparative Industry Analysis & Classification Framework Pharma AI Stock Index Declining Efficiency of R&D in Pharma Corporations Top-20 AI in Drug Discovery Investors 6 Deep …
NEW INDUSTRIAL PHARMACEUTICAL INDUSTRY
Trade and Industry (MITI). The information in this document has been updated as accurately as possible until the date of publication. MINISTRY OF INVESTMENT, TRADE AND INDUSTRY …
Ajanta Pharma Ltd. Fundamental Company Report Including …
Ajanta Pharma Ltd. Industry Position Analysis 6. AJANTA PHARMA LTD. NEWS & EVENTS 6.1. News & PR Activity Analysis 6.2. IR Corporate News 6.3. Marketing News 6.4. Corporate …
Trending and Out-of-Trend results in pharmaceutical industry
which parameters should be subject to trending analysis such as: data obtained from assay analysis, dissolution, other quality metrics, key performance indicators (KPI). The parameters …
Pharmaceutical Competitive Intelligence - Pharma Marketing …
experiences drawn from the pharma CI world. What is Competitive Intelligence? “Most of what is termed CI in the pharma industry is really market research—primary or secondary data that is …
SAS Programming in the Pharmaceutical Industry
Consortiam, is a standards organization for the clinical data field. [12] Part of this standard consists of the Analysis Data Model, which includes items such as variable name, label, data …
